特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
321904

東部ウマ脳炎 : パイプライン分析

Eastern Equine Encephalitis - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 41 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
東部ウマ脳炎 : パイプライン分析
出版日: 2020年06月30日
発行: Global Markets Direct
ページ情報: 英文 41 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

東部ウマ脳炎は、蚊が媒介となる感染症であり、アルボウイルスである東部ウマ脳炎ウイルスが原因です。発熱、頭痛等の軽度な症状から、錯乱・失見識・こん睡など重篤なものまで広い症状が現れます。

当レポートでは、東部ウマ脳炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

東部ウマ脳炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • AlphaVax, Inc.
  • AltraVax Inc.
  • EpiVax, Inc.
  • Profectus BioSciences, Inc.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 分子タイプ別

薬剤のプロファイル

  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • TSI-GSD-104

開発休止中のプロジェクト

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Eastern Equine Encephalitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Eastern Equine Encephalitis - Pipeline by Bavarian Nordic A/S, H1 2020
  • Eastern Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H1 2020
  • Eastern Equine Encephalitis - Pipeline by Ridgeback Biotherapeutics LP, H1 2020
  • Eastern Equine Encephalitis - Dormant Projects, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Eastern Equine Encephalitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12315IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eastern Equine Encephalitis - Pipeline Review, H1 2020, provides an overview of the Eastern Equine Encephalitis (Infectious Disease) pipeline landscape.

Eastern equine encephalitis is a disease that is spread to humans by infected mosquitoes. Eastern equine encephalitis is caused by the Eastern equine encephalitis virus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eastern Equine Encephalitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Eastern Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eastern Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Eastern Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Eastern Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eastern Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eastern Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eastern Equine Encephalitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eastern Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Eastern Equine Encephalitis - Overview
  • Eastern Equine Encephalitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Eastern Equine Encephalitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Eastern Equine Encephalitis - Companies Involved in Therapeutics Development
  • Bavarian Nordic A/S
  • Profectus BioSciences Inc
  • Ridgeback Biotherapeutics LP
  • Eastern Equine Encephalitis - Drug Profiles
  • EIDD-2801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • encephalitis (trivalent,virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • equine encephalitis (trivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • equine encephalitis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Eastern Equine Encephalitis and Venezuelan Equine Encephalitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Myd88 for Infectious Diseases, Inflammation, Septic Shock and Toxic Shock - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TSI-GSD-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Eastern Equine Encephalitis - Dormant Projects
  • Eastern Equine Encephalitis - Product Development Milestones
  • Featured News & Press Releases
  • Apr 18, 2019: UofL researcher developing drug to treat emerging encephalitis viruses
  • Jan 24, 2019: Bavarian Nordic advances development of equine encephalitis virus vaccine
  • Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.